Clinical observation on the treatment of male neoplastic anemia with Yixuesheng capsule (益血生胶囊) combined with recombination human erythropoietin
- 36 Downloads
- 1 Citations
Abstract
Objective
To explore the efficacy and mechanism of Yixuesheng capsule (益血生胶囊, YXS) combined with recombination human erythropoietin (RHE) in treating male neoplastic anemia (NA).
Methods
Sixty-five patients were randomized into two groups, the 33 patients in the treated group treated with a combined therapy of YXS and RHE, and the 32 in the control group treated with RHE alone, all for 12 weeks. Related clinical indexes, including hemoglobin (Hgb), red blood cell (RBC), hematocrit (HMC), testosterone (T), estradiol (E2) and prolactin (PRL), were measured before and after treatment.)
Results
After treatment, Hgb in the treated group and the control group was 108±5 g/L and 104±8 g/L respectively, showing marked improvement as compared with that before treatment (P<0.01), and the improvement in the former was more significant than that in the latter (P<0.05). Further, the level of T was also increased in the treated group after treatment (P<0.05), and showed a significant difference from that of the control group (P<0.05).
Conclusions
YXS capsule combined with RHE shows a better therapeutic effect in treating NA than that of RHE alone, and the effect might be through stimulation by YXS of erythropoiesis which could promote the secretion of testosterone.
Key Words
Yixuesheng capsule recombination human erythropoietin combined therapy testosterone neoplastic anemiaPreview
Unable to display preview. Download preview PDF.
References
- 1.Glasyp J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 1999;13:461–473.Google Scholar
- 2.Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998;25(3 suppl 7):35–38.PubMedGoogle Scholar
- 3.Zhang HY, Meng QX, Liu J, Pang LP, Yang BQ. Study on the serum erythropoietin and testoserone in patients with anemia of cancer. Chin J Prim Med Pharm (Chin) 2004;11(3):295–296.Google Scholar
- 4.Zhang ZN, Shen T, ed. Standard for diagnosis and therapeutic efficacy evaIuation of hematopathy. 2nd ed. Beiiing: Publishing House of Science; 1998:1–5.Google Scholar
- 5.Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999;92:153–160.PubMedCrossRefGoogle Scholar
- 6.Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–1647.PubMedGoogle Scholar
- 7.Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649–659.PubMedCrossRefGoogle Scholar
- 8.Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–2874.PubMedGoogle Scholar
- 9.Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–2882.PubMedGoogle Scholar